CN100341549C - Medicinal preparation for treating or preventing beart brain blood vessel diseases - Google Patents
Medicinal preparation for treating or preventing beart brain blood vessel diseases Download PDFInfo
- Publication number
- CN100341549C CN100341549C CNB2004100796116A CN200410079611A CN100341549C CN 100341549 C CN100341549 C CN 100341549C CN B2004100796116 A CNB2004100796116 A CN B2004100796116A CN 200410079611 A CN200410079611 A CN 200410079611A CN 100341549 C CN100341549 C CN 100341549C
- Authority
- CN
- China
- Prior art keywords
- present
- medicinal
- preparation
- sanguis draxonis
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a traditional Chinese medicine preparation, particularly to a compound traditional Chinese medicine preparation for treating and preventing cardiovascular and cerebrovascular diseases. Medicinal active ingredients and medicinal auxiliary materials are prepared into an oral preparation by the conventional technology to obtain the medicinal preparation of the present invention, wherein the medicinal active ingredients contain 15 to 85 wt% of dragon's blood and 85 to 15 wt% of safflower oil. The medicinal preparation of the present invention is used for preventing and treating coronary heart disease, angina pectoris, obstruction of qi in the chest and cardiodynia caused by heart blood stasis, oppression in chest, stabbing pain, atherosclerosis, hyperlipoidemia, cerebral thrombosis, cerebral ischemia, etc., and has the advantages of easy absorption and metabolism, difficult degradation by gastric acid, high bioavailability, obvious effect, high curative effect, easy taking and convenient storage. The present invention is an advanced Chinese patent medicine.
Description
Technical field
The present invention relates to a kind of Chinese medicine preparation, especially a kind of Chinese traditional compound medicine with treatment and the effect of prevention cardiovascular and cerebrovascular disease.
Background technology
Sanguis Draxonis at the medicinal history in existing more than 1,500 year of China, has promoting blood circulation to remove blood stasis, effects such as pain relieving, hemostasis, promoting tissue regeneration and ulcer healing as traditional rare Chinese medicine.For oral administration cure mainly that congestion swells and ache, amenorrhea, dysmenorrhea, external cures mainly traumatic hemorrhage, ulcer being unable to heal, anal fistula swells and ache.The Ji Yuan of China's Sanguis Draxonis mainly makes from the process of resin of babassu Sanguis Draxonis and the multiple dracaena plant of Liliaceae, mainly contain compositions such as flavonoid, saponins, sterols, terpenoid, pharmacological action shows that Sanguis Draxonis has antioxidation, anti-inflammatory analgetic, activating blood circulation to dissipate blood stasis, antifungal, antibacterial, anticoagulant, antithrombotic, promote the epidermis repair, suppress alpha-glucosidase.Modern medicine study confirms that Sanguis Draxonis has the body of improvement microcirculation, adjusts the body metabolism, improves effects such as immunity of organisms function, has dual regulation aspect the treatment " mass formed by blood stasis ".
Sanguis Draxonis is usually used in treating surgery, traumatology traumatic injury, chronic ulcer does not clinically heal, and the oral digestion road is hemorrhage, peptic ulcer and various gastritis; Gynaecopathia, angina pectoris; Disease such as cerebral thrombosis, thromboangiitis obliterans.Blood sugar lowering, blood fat reducing.Yet people have only used Sanguis Draxonis single preparations of ephedrine kind at present: capsule, powder, sheet, buccal tablet, enteric coated capsule.
Summary of the invention
The objective of the invention is to propose a kind of treatment of making by two kinds of Chinese medicine compound that has remarkable potentiation and have no side effect or the pharmaceutical preparation of prevention cardiovascular and cerebrovascular disease.
The pharmaceutical preparation of treatment of the present invention or prevention cardiovascular and cerebrovascular disease is the oral formulations that is formed through conventional prepared by medicinal active ingredient and pharmaceutic adjuvant, and described medicinal active ingredient is made up of following raw materials by weight percent medicine: Sanguis Draxonis 15-85%, safflower oil 85-15%.
Above-mentioned Sanguis Draxonis can be Benexate Hydrochloride, also can be the Sanguis Draxonis without enclose.Sanguis Draxonis is an excretory resin or derive from the resin that the resiniferous wood of liliaceous plant Dracaena cochinchinensis Dracaena cochinchienesis (Lour) S.C chen obtains through extraction in the Palmae Daemonorops liana Sanguis Draxonis Daemonorops draco BL. fruit, in methanol, ethanol and sig water dissolving, insoluble at water, ether and dilute acid soln.
Above-mentioned safflower oil is to make with extra care through technologies such as squeezings from the seed of Chinese medicine Flos Carthami (Carthamus tinctorius.L) to form, and quality meets American Pharmacopeia (24 editions): safflower oil (Safflower Oil).Flos Carthami has another name called Flos Carthami, yellow Cymbidium ensifolium (L.) Sw., chrysanthemum Flos Carthami.Li Shizhen (1518-1593 A.D.) claims its " function with spend with " in Compendium of Material Medica, Flos Carthami has GUIXIN, Liver Channel, tool promoting blood circulation to restore menstrual flow, the effect of eliminating stasis to stop pain.Modern pharmacological research shows that it has effects such as blood pressure lowering, blood fat reducing, antithrombotic.The oil that extracts from Semen Flos Carthami contains following composition: myristic acid 0～1.5%, Palmic acid 2.1～8.4%, stearic acid 1～6.5%, oleic acid 7～37.6%, linoleic acid 56.7～80%, vitamin E, plant sterol.The safflower oil acid number is low, viscosity is little, condensation point low (13 ℃～-26 ℃), oil colours are shallow, limpid clear and bright, and FAO (Food and Agriculture Organization of the United Nation) began Semen Flos Carthami formally to be listed in as oil crop within the statistical item of " FAO (Food and Agriculture Organization of the United Nation) (FAO) produces yearbook Semen Flos Carthami production statistical table " in 1973.Owing to do not contain or contain few linolenic acid in the safflower oil composition, have good colour retention and not yellow property, experiment shows, safflower oil can reduce total fat, cholesterol, triglyceride and beta lipoprotein level in the serum significantly, and phospholipid is not had influence, the long-term edible blood fat reducing that has, effect such as vessel softening, stabilizing blood pressure, and can moisturize, the swollen pain relieving of loosing is stimulated the menstrual flow and is dispeled the wind.
Above-mentioned pharmaceutic adjuvant is a conventional pharmaceutic adjuvant of making oral formulations usually, and manufacture method also is conventional process.
The present invention is a compatibility of selecting Sanguis Draxonis and Flos Carthami oil for use, by its significant potentiation, makes the medicine of a kind of obvious results treatment or prevention cardiovascular and cerebrovascular disease, and this medicine also can be used for the treatment of or prevention and digestive system disease.Pharmaceutical preparation of the present invention can be peroral dosage forms such as soft capsule, liquid capsule, tablet, capsule, granule.Pharmaceutical preparation of the present invention is used for obstruction of qi in the chest and cardialgia due to prevention and treatment coronary heart disease, angina pectoris, the stagnation of heart-blood, twinge uncomfortable in chest, diseases such as atherosclerosis, hyperlipidemia, cerebral thrombosis, cerebral ischemia.And easily absorb metabolism, be difficult for being degraded by gastric acid, the bioavailability height, produce effects is fast, curative effect is high, and easily take, just preserve, be a kind of advanced person's Chinese patent medicine.
By the side's of tearing open analysis, product of the present invention has been carried out following pharmacodynamic study and anxious poison research:
1, pharmaceutical preparation antiplatelet effects of the present invention and anti thrombotic action
The influence test of stomach to rabbit platelet aggregation function irritated in pharmaceutical preparation of the present invention, show that the present invention can obviously suppress ADP and the inductive platelet aggregation of PAF through irritating stomach, compare with isodose Sanguis Draxonis or safflower oil, the antiplatelet effects of this compound recipe uses Sanguis Draxonis or safflower oil more separately, effect significantly strengthens, test shows the obvious prolong rats carotid artery occlusion time of compound dragon's blood soft capsule of height, middle dosage simultaneously, reduce the dead mouse number that ADP causes, the pharmaceutical preparation of the present invention of 0.9g/kg promptly has tangible thromboembolism preventing effect.
2, pharmaceutical preparation of the present invention is to the influence of blood coagulation system
Result of the test shows, pharmaceutical preparation of the present invention has than Sanguis Draxonis or more significant shortening mouse tail point bleeding time of safflower oil folk prescription and shortens the clotting time effect, the astringing to arrest bleeding effect is strong than Sanguis Draxonis, to the dual regulation that shows of blood coagulation system, point out pharmaceutical preparation of the present invention can not cause tangible bleeding tendency.
3, pharmaceutical preparation toxicity test of the present invention
200 times of oral administrations of the clinical daily dose of rat usefulness the present invention 30 days, the weight of animals increases normally during administration, and the toxic reaction appears in the end.Clinical treatment dosage 0.06g/kg is safe.Compare with matched group, of the present invention group of heavy obviously increase of female rats spleen, the visible spleen folliculus of microscopy germinal center enlarges, medullary cord mesoplasmatocyte showed increased, the equal showed increased of multinucleated giant cell and skein cell shows that the present invention has the effect of enhancing humoral immunization.
The specific embodiment
Embodiment 1: compound capsules
One, medicinal liquid preparation: getting percentage by weight is 31% Sanguis Draxonis, 69% safflower oil, adds appropriate amount of auxiliary materials, carries out the medicinal liquid preparation.
Safflower oil is an active medicine in the present embodiment, is again the substrate of disperseing Sanguis Draxonis.
Wetting agent is surfactant-based in the described pharmaceutic adjuvant, as one or more of Tweens, spans etc.Suspending agent is selected the fixed substance that can increase dispersion medium viscosity for use, as one or more of mixture such as Cera Flava, aluminum monostearate, fiber-like, 10%～30% oily wax, agar, xanthan gum.Antiseptic can be sorbic acid, sorbic acid methyl ester, methyl parahydroxybenzoate, ethylparaben, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, benzyl p-hydroxybenzoate, in light yl benzoic acid methyl ester sodium, benzoic acid, the benzyl alcohol one or more.
Sanguis Draxonis is pulverized the back and is crossed 100～200 mesh sieves.Adopt high rotating speed colloid mill (rotating speed greater than 3000 change), Sanguis Draxonis, safflower oil and adjuvant are placed in the stainless steel cask stir evenly earlier, ground 3 hours in the colloid mill that reinjects after in the pasty state,, be not sedimentation suspendible emulsion to complete even.
Two, glue preparation:
Select high-quality gelatin (freeze power 〉=12 °, pulling force 〉=100 °), high-quality glycerol (meeting the Chinese Pharmacopoeia requirement) and purification distilled water for use, three's ratio is: 100: 46.7: 85, above-mentioned glue raw material is poured into respectively in the melten gel jar, vacuum decompression is to 0.85MPa, heat 70 ℃ and stirred 1 hour, treat to add antiseptic by recipe quantity again after gelatin melts fully, stir evenly, inject 45 ℃ of constant temperature of steady glue bucket 3 hours, and prevented the glue sclerosis.
Three, soft capsule preparation:
Glue, medicinal liquid material are injected the encapsulating machine charging basket, the suitable volume mould of preliminary election, temperature and humidity remains on 20 ℃ and 75%RH in the control room, start compacting soft capsule; The soft capsule that main frame is suppressed is out delivered to rotary drier typing rotating cage through conveyer belt, enters dry rotating cage drying after the drying of finalizing the design again, makes water content≤9%; Wash the ball after drying with 95% ethanol, pack after quality inspection is qualified, vanning had both got finished product.
Embodiment 2: compound capsules
Getting percentage by weight is 50% Sanguis Draxonis, 50% safflower oil, and Sanguis Draxonis is pulverized the back and crossed 160～200 mesh sieves, adds in the safflower oil, stirs, and adds appropriate amount of auxiliary materials again, carries out the medicinal liquid preparation.Make soft capsule according to embodiment 1 method.
Embodiment 3: compound tablet
Getting percentage by weight is 80% Sanguis Draxonis, 20% safflower oil, and Sanguis Draxonis is pulverized the back and stirred with safflower oil, adds appropriate amount of auxiliary materials again, makes compound tablet according to the conventional tablet production method.
Embodiment 4: compound capsule
Getting percentage by weight is 20% Sanguis Draxonis, 80% safflower oil, and Sanguis Draxonis is pulverized the back and stirred with safflower oil, adds appropriate amount of auxiliary materials again, makes the compound capsule agent according to conventional capsule production method.
More than implement profit only for the present invention is further illustrated, and scope of the present invention is not subjected to the limitation of illustrated embodiment.
Claims (3)
1, the pharmaceutical preparation of a kind of treatment or prevention cardiovascular and cerebrovascular disease, be by medicinal active ingredient and pharmaceutic adjuvant through the oral formulations that conventional prepared forms, it is characterized in that described medicinal active ingredient is made up of following raw materials by weight percent medicine: Sanguis Draxonis 15-85%, safflower oil 85-15%.
2, according to the pharmaceutical preparation of described treatment of claim 1 or prevention cardiovascular and cerebrovascular disease, it is characterized in that described Sanguis Draxonis is a Benexate Hydrochloride.
3,, it is characterized in that described Sanguis Draxonis is the Sanguis Draxonis without enclose according to the pharmaceutical preparation of described treatment of claim 1 or prevention cardiovascular and cerebrovascular disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100796116A CN100341549C (en) | 2004-12-07 | 2004-12-07 | Medicinal preparation for treating or preventing beart brain blood vessel diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100796116A CN100341549C (en) | 2004-12-07 | 2004-12-07 | Medicinal preparation for treating or preventing beart brain blood vessel diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1785333A CN1785333A (en) | 2006-06-14 |
| CN100341549C true CN100341549C (en) | 2007-10-10 |
Family
ID=36783001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100796116A Expired - Fee Related CN100341549C (en) | 2004-12-07 | 2004-12-07 | Medicinal preparation for treating or preventing beart brain blood vessel diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100341549C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105663416A (en) * | 2016-03-12 | 2016-06-15 | 吴申龙 | Traditional Chinese medicine composition for treating heart blood stasis type chest obstruction and preparation method thereof |
| CN111773355A (en) * | 2020-07-13 | 2020-10-16 | 杨妮娜 | Traditional Chinese medicine formula for reducing arteriosclerotic plaque and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1081897A (en) * | 1993-04-24 | 1994-02-16 | 王筱溥 | Musk naotongsu |
| CN1114219A (en) * | 1995-03-08 | 1996-01-03 | 鲁洪艺 | Process for preparing Chinese drugs for curing coronary heart disease, angina pectoris and myocardiac infarction |
-
2004
- 2004-12-07 CN CNB2004100796116A patent/CN100341549C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1081897A (en) * | 1993-04-24 | 1994-02-16 | 王筱溥 | Musk naotongsu |
| CN1114219A (en) * | 1995-03-08 | 1996-01-03 | 鲁洪艺 | Process for preparing Chinese drugs for curing coronary heart disease, angina pectoris and myocardiac infarction |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1785333A (en) | 2006-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE102008034944B4 (en) | microemulsion | |
| CN101842089A (en) | Methods for stimulating synthesis of pro-collagen or collagen and hyaluronic acid | |
| CN101062022B (en) | Colchicine patch absorbing from skin for treating acute goute arthritis and the preparing method thereof | |
| CN1010828B (en) | Process for preparing drugs of treating traumatic wound | |
| CN100341549C (en) | Medicinal preparation for treating or preventing beart brain blood vessel diseases | |
| CN103520012A (en) | Application of baicalin in preparation of oral care product | |
| KR20160083299A (en) | Ointment composition of the aerial part of Glechoma grandis Kuprianova var. longituba Kitagawa on scalded wound healing | |
| DE3417576A1 (en) | RETARD FORMS OF ALPHA- (2,5-DIMETHOXY-PHENYL) -SS-GLYCINAMIDOAETHANOL AND METHOD FOR THE PRODUCTION THEREOF | |
| CN1686389A (en) | Danhong drip pill prepared from salvia root and carthamus and its preparation method | |
| CN102949415B (en) | Propolis fat emulsion preparation and preparation method thereof | |
| CN1899388A (en) | Shuangdan soft capsule and its preparing method | |
| CN101468059A (en) | Gel patch for treating myopia and preparation method thereof | |
| CN106806713A (en) | A kind of Chinese and Western for alleviating periostitis symptom combines medicine oil and preparation method thereof | |
| CN108619210A (en) | Promote the composition and its preparation method and application of wound healing | |
| CN1927370A (en) | Baofukang vaginal soft capsule and its preparing process | |
| CN101468055A (en) | Gel patch for preventing and treating cerebral thrombosis and preparation method thereof | |
| CN1543942A (en) | Haw leaf general flavone soft capsule and preparation thereof | |
| CN1679643A (en) | Aloe trauma curing gel, preparation and use thereof | |
| CN1191747A (en) | Congelation treating suspension | |
| CN101468135A (en) | Gel patch for treating hyperlipemia and method for preparing the same | |
| RU2195305C1 (en) | Biologically active additive | |
| RU2248198C2 (en) | Anti-burn preparation | |
| CN2863110Y (en) | Double-pellet soft capsule | |
| CN1481883A (en) | Fleabane soft capsule formulation and its preparation method | |
| CN1029586C (en) | Preparation method for multifunctional and instant effecting ointment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: WUZHOU GUANGXI SANHE PHARMACEUTICAL INDUSTRY CO., Free format text: FORMER OWNER: YUNNAN LONGSHENG MEDICINE SCI. + TECH. CO., LTD. Effective date: 20140522 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 650000 KUNMING, YUNNAN PROVINCE TO: 543002 WUZHOU, GUANGXI ZHUANG AUTONOMOUS REGION |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20140522 Address after: Two the Guangxi Zhuang Autonomous Region Wuzhou Fumin road 543002 No. 28 Patentee after: Guangxi Wuzhou Sanhe Pharmaceutical Co.,Ltd. Address before: 17 A block, 650000 Changchun garden, Renmin Road, Panlong District, Yunnan, Kunming, China Patentee before: Yunnan Longsheng Medicine Science &Technology Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071010 Termination date: 20161207 |